My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: usually no — compounded GLP‑1s are not the safest or most reliable first option after a Wegovy denial. There are better, safer paths to try first.

Why compounded GLP‑1s are risky

• Compounded semaglutide/tirzepatide preparations are not FDA‑approved. That means no guaranteed potency, sterility, packaging, label instructions or adverse‑event oversight.
• Several safety and contamination concerns have been reported with compounded biologicals; dosing errors or poor cold‑chain handling can cause harm.
• Insurers and clinicians may object to using compounded biologics for weight loss, making follow‑up and coverage problematic.

Safer alternatives to try first (specific names and services)

1. Appeal the denial / prior‑authorization strategies

   • Ask your prescriber to submit a formal appeal or prior‑authorization request with a medical‑necessity letter citing your BMI, comorbidities, treatment history, and relevant guidelines.
   • Ask about an external or independent review if internal appeal fails.

2. Manufacturer assistance and copay programs

   • Novo Nordisk Wegovy savings programs and NovoCare patient support — they can help with copay cards, starter dosing programs, and patient‑assistance for eligible people.
   • Eli Lilly (for Mounjaro or Zepbound) — LillyCares and patient support programs if your clinician considers tirzepatide appropriate.
   • These programs are often faster, reliable, and keep you on FDA‑approved products.

3. Try another FDA‑approved GLP‑1 that your plan will cover

   • Examples: Ozempic (semaglutide), Rybelsus (oral semaglutide), Mounjaro (tirzepatide) or Zepbound (tirzepatide for weight loss). Some are indicated for diabetes but are used for weight management; your clinician can discuss appropriate choice and dosing.
   • Ask your insurer which GLP‑1s they will cover and whether a step‑therapy exception is possible.

4. Discount and coupon services

   • GoodRx and SingleCare can reduce out‑of‑pocket cost for some branded products when insurance won’t cover them.
   • Check manufacturer copay cards (Novo Nordisk, Lilly) first — often deeper savings than general coupons.

5. Other resources

   • NeedyMeds, RxAssist and 340B clinics for low‑cost access programs.
   • Consider enrollment in clinical trials of newer weight‑loss drugs if eligible.

When compounded GLP‑1s might be considered — and how to reduce risk

• Only consider a compounded product if all safer options are exhausted, and only through a reputable, state‑licensed compounder that follows USP sterile compounding standards (USP <797>/<800>) or a 503B outsourcing facility. Ask the pharmacy for:
  • Certificate of analysis for each batch and evidence of sterility testing.
  • Source of the active pharmaceutical ingredient (API).
  • Cold‑chain handling and shipping details.
  • Pharmacist credentials and facility licensure; return/refund policies.
  • Clear dosing instructions and prescribing syringe/pen compatibility.
• Avoid buying injections from online marketplaces or sources that cannot prove lot testing and chain of custody.

Regulatory note

• The FDA has warned that compounded semaglutide products are not approved and highlighted safety/quality concerns. That’s why the FDA‑approved branded drugs are the safer route.

If you want, I can:

• Help you draft a prior‑authorization/appeal letter your clinician can use.
• Look up Wegovy/NovoCare support contact info and relevant copay or patient‑assistance links.
• Help compare likely out‑of‑pocket costs (using GoodRx estimates) for alternative GLP‑1s your insurer might cover.

Which would you like to do next?